Kymera Therapeutics had a nice pop today and is currently up 4.46% we'll see if the cash keeps flowing in. It looks like KYMR may be interacting with a slightly angled support line. This area could represent a pivot point that it moves up from. Kymera Therapeutics hasn't been that impressive in terms of its 3 month momentum, it has been breaking down lower so we'll see if it can turn things around and move up from here.
If the price bounces off of the support and moves up it'll probably head up to the $33.56 level, at which point it may hit some selling pressure. If it punches through this support level, it can easily push down to $20.89 where it may meet further support, hopefully it can consolidate around that point.
The analysts are pretty neutral on Kymera Therapeutics right now, so not much useful information here. The current Analysts Sentiment Score is 2.84. Most companies range between (-200 to 200).
Here's a break down of the latest rating changes. Oppenheimer initiated a rating of Outperform on 2024-04-22 and added a price target of $53.00. Truist Financial decided to move up their price target on 2024-03-01 to $54.00 which is a 31.71% increase. Piper Sandler gave a boost to their price target and moved to $56.00 from $39.00 on 2024-02-27. JPMorgan Chase & Co. provided a price target boost of 38.24% to $47.00 from $34.00 on 2024-02-23. On 2024-02-23 Stifel Nicolaus increased their price target by 57.14% to $55.00. On 2024-02-15 Wolfe Research started covering Kymera Therapeutics with a rating of Peer Perform. Bank of America released a downgrade on 2024-01-03 from Buy to Neutral and decided to decrease their price target by -33.33% down to $30.00. On 2023-12-19 Wells Fargo & Company downgraded Kymera Therapeutics from Overweight to Equal Weight and they set their price target at $26.00. Morgan Stanley announced a lowering of their price target to $24.00 from $37.00 on 2023-11-13. HC Wainwright announced a lowering of their price target to $30.00 from $85.00 on 2023-11-03.
| Company | Ratings Score
?
Composite analyst sentiment score
|
Positive Ratings | Negative Ratings | Boost Price Target | Lower Price Target |
|---|---|---|---|---|---|
| KYMR | 2.84 | 2.17 | -1.19 | 5.81 | -1.12 |
| Company | YOY Growth Score (typical -20 to +20) | Revision Directions (-6 to +6) |
|---|---|---|
| KYMR | 0.00 | 0.00 |
We take into account several different measures of short interest to create a composite score. These measures are shown in the chart below. Short selling is when investors are betting against a stock. We compile these factors to create a dynamic Short Score - this can indicate poor sentiment, internal problems with a company or industry and the anticipation of future price declines. We look at the short interest percent, days to cover, the rate of change and total shares sold short.
| Company | Short Score (typical 1-15)
?
We take into account several different measures and attributes of short interest to create a composite sentiment score. typical range (0 - 30)
|
Short Interest | Days to Cover | Rate of Change | Shares Short |
|---|---|---|---|---|---|
| KYMR | 13.66 | %13.2106 | 14.2 | -0.66 | 7320000 |
Social Sentiment is an aggregation of several different factors such as news, articles, blogs, user content, ratings, etc. Which is shown in the chart below. It may become predictive of a reversal if price and the sentiment diverge. Broader market forces may push prices up or down but if market participants maintain a different view on a specific stock, it may be taken as an opportunity to buy or sell in those cases.
| Ticker | Social Sentiment(1-10) |
|---|---|
| KYMR |
| Company | Score | 1 Day% | 5 Day | 1 Month | 3 Month | 6 Month | 1 Year | RSI | 3mo S-momo ? | 6mo S-momo | 1yr S-momo | Resistance ? | Support | Demark Sell ? | Demark Buy | Short Interest Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PRTA | Prothena Corporation plc | 0.89 | 3.41 | -6.69 | -19.76 | -7.68 | -27.09 | -49.31 | 46 | -41.03 | -62.42 | -62.06 | -66060.17 | -1853.82 | 0 | 0 | 11.1209 |
| VCYT | Veracyte, Inc. | 0.84 | 1.93 | -3.12 | -7.32 | -30.59 | -9.06 | 46.90 | 40 | 1.02 | 1.28 | 9.27 | -7486.40 | 175.50 | 0 | 0 | 4.97884 |
| VRNS | Varonis Systems, Inc. | 0.83 | 1.61 | -0.31 | 0.97 | -7.91 | -24.46 | -8.76 | 58 | -109.66 | -30.30 | -18.75 | -16618.03 | -2134.99 | 0 | 0 | 5.39701 |
| YMAB | Y-mAbs Therapeutics, Inc. | 0.8 | 6.67 | -3.23 | -8.57 | -38.54 | -63.66 | -67.48 | 47 | -130.25 | -68.35 | -78.83 | -71339.03 | -440.23 | 0 | 0 | 10.5121 |
| IDYA | IDEAYA Biosciences, Inc. | 0.74 | 10.70 | -6.20 | -14.26 | -36.36 | -46.79 | -60.60 | 21 | -247.89 | -198.34 | -122.34 | -49602.39 | 0.00 | 0 | 0 | 11.9529 |
| DNLI | Denali Therapeutics Inc. | 0.74 | 11.80 | -3.24 | -15.55 | -30.68 | -52.08 | -29.10 | 42 | -44.67 | -44.39 | -23.95 | -34122.65 | 0.00 | 0 | 0 | 11.2371 |
| TXG | 10x Genomics, Inc. Class | 0.73 | 2.08 | -5.95 | -22.84 | -44.41 | -58.47 | -75.49 | 23 | -89.10 | -103.23 | -120.26 | -69465.17 | 0.00 | 0 | 0 | 8.00406 |
How to use: use the research links to research the asset. Then simply type in a score for each category between (01, 02, 03, 04, 05). 05 being the most bullish and 01 being the most bearish. It will automatically calculate the average and combine it with the technical score to create an overall score to rank prospects by. You can also type notes into each field.
